Baxter International Inc. (NYSE:BAX) Shares Sold by Bokf Na

Bokf Na lowered its stake in Baxter International Inc. (NYSE:BAX) by 22.2% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 8,768 shares of the medical instruments supplier’s stock after selling 2,495 shares during the period. Bokf Na’s holdings in Baxter International were worth $258,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. CoreFirst Bank & Trust acquired a new stake in Baxter International during the fourth quarter valued at approximately $26,000. Riverview Trust Co increased its holdings in shares of Baxter International by 5,488.2% in the 4th quarter. Riverview Trust Co now owns 950 shares of the medical instruments supplier’s stock valued at $28,000 after acquiring an additional 933 shares during the last quarter. CKW Financial Group raised its position in shares of Baxter International by 19.3% during the 4th quarter. CKW Financial Group now owns 2,625 shares of the medical instruments supplier’s stock valued at $77,000 after acquiring an additional 425 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in Baxter International by 61.2% during the fourth quarter. Farther Finance Advisors LLC now owns 4,060 shares of the medical instruments supplier’s stock worth $118,000 after purchasing an additional 1,541 shares during the last quarter. Finally, Oarsman Capital Inc. acquired a new position in Baxter International in the fourth quarter worth $157,000. Institutional investors and hedge funds own 90.19% of the company’s stock.

Baxter International Trading Down 1.0 %

NYSE:BAX opened at $30.90 on Friday. The stock has a market cap of $15.85 billion, a price-to-earnings ratio of -24.14, a PEG ratio of 0.93 and a beta of 0.63. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.09 and a current ratio of 1.43. Baxter International Inc. has a 1 year low of $26.25 and a 1 year high of $40.49. The business has a fifty day moving average of $31.64 and a 200-day moving average of $31.98.

Baxter International (NYSE:BAX) last announced its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.14. Baxter International had a negative net margin of 5.05% and a positive return on equity of 16.67%. The firm had revenue of $2.63 billion during the quarter, compared to analyst estimates of $2.59 billion. During the same quarter in the prior year, the firm posted $0.65 EPS. Baxter International’s revenue was up 5.4% compared to the same quarter last year. Equities analysts predict that Baxter International Inc. will post 2.48 earnings per share for the current year.

Baxter International Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 1st. Shareholders of record on Friday, May 30th will be paid a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 2.20%. The ex-dividend date is Friday, May 30th. Baxter International’s payout ratio is currently -61.82%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on BAX shares. JPMorgan Chase & Co. reduced their price target on shares of Baxter International from $38.00 to $36.00 and set a “neutral” rating on the stock in a research report on Friday, February 21st. The Goldman Sachs Group started coverage on shares of Baxter International in a report on Wednesday, February 26th. They issued a “buy” rating and a $42.00 target price on the stock. Barclays increased their price target on Baxter International from $39.00 to $41.00 and gave the stock an “overweight” rating in a research report on Monday, March 10th. Argus upgraded Baxter International from a “hold” rating to a “buy” rating in a research report on Monday, February 24th. Finally, Wells Fargo & Company lowered their price objective on Baxter International from $36.00 to $33.00 and set an “equal weight” rating for the company in a research note on Friday, May 2nd. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. According to MarketBeat, Baxter International currently has a consensus rating of “Hold” and a consensus price target of $37.25.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.